Certara, Inc. (CERT)
NASDAQ: CERT · Real-Time Price · USD
14.27
-0.18 (-1.25%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Certara Revenue
In the year 2024, Certara had annual revenue of $385.15M with 8.70% growth. Certara had revenue of $100.36M in the quarter ending December 31, 2024, with 14.03% growth.
Revenue (ttm)
$385.15M
Revenue Growth
+8.70%
P/S Ratio
5.93
Revenue / Employee
$249,125
Employees
1,546
Market Cap
2.30B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CERT News
- 9 days ago - Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report - Benzinga
- 9 days ago - Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing - GlobeNewsWire
- 12 days ago - Buy Certara After The FDA Announcement - Seeking Alpha
- 12 days ago - What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
- 22 days ago - Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities - GlobeNewsWire
- 7 weeks ago - Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions - GlobeNewsWire
- 2 months ago - Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Certara Reports Fourth Quarter 2024 Financial Results - GlobeNewsWire